| Ryan Charles Roubion, MD | |
|
3001 Division St Ste 204, Metairie, LA 70002-5855 | |
| (504) 541-5800 | |
| (504) 541-5801 |
| Full Name | Ryan Charles Roubion |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 7 Years |
| Location | 3001 Division St Ste 204, Metairie, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154862456 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 337608 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tulane Medical Center | New orleans, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metairie Orthopedics And Sports Medicine | 6406189869 | 3 |
News Archive
Sientra, a privately-held medical device company focused on the aesthetic and plastic surgery markets, announced today that it closed on its $65 million Series C financing led by Abingworth and with participation by Clarus Ventures, OrbiMed Advisors and all other insiders.
Allscripts, the leading provider of clinical software, information and connectivity solutions for physicians, and Eclipsys, a leading enterprise provider of solutions and services for hospitals and clinicians, today announced a definitive agreement to merge in an all-stock transaction valued at approximately $1.3 billion.
Berson's medium pressure UV systems are being used in a trial in the Netherlands to treat hospital wastewater prior to discharge. In the trial, UV is applied in combination with hydrogen peroxide (H2O2) to generate OH- radicals in a so-called "Advanced Oxidation Process" (AOP). The very reactive OH- radicals attack the pharmaceutical residues in the wastewater, breaking them down into H2O, CO2 and harmless metabolites.
Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.
› Verified 2 days ago
| Entity Name | Metairie Orthopedics & Sports Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184288128 PECOS PAC ID: 6406189869 Enrollment ID: O20190618000520 |
News Archive
Sientra, a privately-held medical device company focused on the aesthetic and plastic surgery markets, announced today that it closed on its $65 million Series C financing led by Abingworth and with participation by Clarus Ventures, OrbiMed Advisors and all other insiders.
Allscripts, the leading provider of clinical software, information and connectivity solutions for physicians, and Eclipsys, a leading enterprise provider of solutions and services for hospitals and clinicians, today announced a definitive agreement to merge in an all-stock transaction valued at approximately $1.3 billion.
Berson's medium pressure UV systems are being used in a trial in the Netherlands to treat hospital wastewater prior to discharge. In the trial, UV is applied in combination with hydrogen peroxide (H2O2) to generate OH- radicals in a so-called "Advanced Oxidation Process" (AOP). The very reactive OH- radicals attack the pharmaceutical residues in the wastewater, breaking them down into H2O, CO2 and harmless metabolites.
Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Charles Roubion, MD 3001 Division St Ste 204, Metairie, LA 70002-5855 Ph: (504) 541-5800 | Ryan Charles Roubion, MD 3001 Division St Ste 204, Metairie, LA 70002-5855 Ph: (504) 541-5800 |
News Archive
Sientra, a privately-held medical device company focused on the aesthetic and plastic surgery markets, announced today that it closed on its $65 million Series C financing led by Abingworth and with participation by Clarus Ventures, OrbiMed Advisors and all other insiders.
Allscripts, the leading provider of clinical software, information and connectivity solutions for physicians, and Eclipsys, a leading enterprise provider of solutions and services for hospitals and clinicians, today announced a definitive agreement to merge in an all-stock transaction valued at approximately $1.3 billion.
Berson's medium pressure UV systems are being used in a trial in the Netherlands to treat hospital wastewater prior to discharge. In the trial, UV is applied in combination with hydrogen peroxide (H2O2) to generate OH- radicals in a so-called "Advanced Oxidation Process" (AOP). The very reactive OH- radicals attack the pharmaceutical residues in the wastewater, breaking them down into H2O, CO2 and harmless metabolites.
Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.
› Verified 2 days ago
Dr. David W. Aiken, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4224 Houma Blvd, Suite 650, Metairie, LA 70006 Phone: 504-456-5152 Fax: 504-456-5019 | |
Dr. Warren Roger Bourgeois Iii, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3939 Houma Blvd, Suite 18, Metairie, LA 70006 Phone: 504-455-0093 Fax: 504-454-3964 | |
Dr. Matko Milicic, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 312 Friedrichs Ave, Metairie, LA 70005 Phone: 504-832-5940 | |
John G Burvant, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3939 Houma Blvd, Suite 21, Metairie, LA 70006 Phone: 504-885-6464 Fax: 504-885-6414 | |
Russell Levy, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 4905 Folse Dr, Metairie, LA 70006 Phone: 504-455-4883 | |
Dr. Bobby L Mimeles, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 4720 S I 10 Service Rd W, Suite 301, Metairie, LA 70001 Phone: 504-885-8225 Fax: 504-885-7642 |